At the news
? NEUTRALIMPACT 2/10 144 filed Nov 2, 2026 at 17:29 ET
Todd Watanabe, an officer of Arcutis Biotherapeutics, filed a Form 144 on November 2, 2026, indicating intent to sell 4,377 shares of common stock with an approximate market value of $139,466. The shares were acquired via restricted stock vesting on November 1, 2026. This is a routine sale following vesting, representing a small fraction of the company's $4.0B market cap.
- Insider Todd Watanabe (officer) filed Form 144 to sell 4,377 shares of common stock.
- Estimated value of proposed sale: $139,466.
- Shares acquired via restricted stock vesting on November 1, 2026.
- Proposed sale date: November 2, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access